Duet Biotherapeutics Inc

Lixte Biotechnology Holdings is a publicly traded therapeutic and diagnostics company that focuses on the improvement of treatment options for life-threatening cancers. The company undertakes various biomedical research activities for the development of drugs for cancers. Founded in 2005, Lixte Biotechnology Holdings is engaged in the development of chemotherapy drugs that target molecular abnormalities of cancers in humans. Based on the discovery of biomarkers for brain cancers by collaborators at the National Institutes of Health, the company evaluates drugs for the treatment of cancer in adults and children. It works in partnership with the National Institute of Neurological Disorders and Stroke to study the effectiveness of lead compounds.

AcuraStem Inc., based in Pasadena, CA, is a pioneering biotechnology company focused on developing innovative treatments for neurodegenerative diseases, including sporadic ALS and FTD. Utilizing their proprietary disease-modeling platform, iNeuroRx, AcuraStem emphasizes a patient-based approach that leads to more effective and broadly applicable therapeutic solutions by generating individual patient models that accurately mimic disease processes. With a commitment to advancing drug development, AcuraStem has made significant strides in the field, as demonstrated by recent presentations from their leadership at prominent research summits. Their work aims to address the limitations of traditional animal models, fostering a deeper understanding of the human mechanisms that drive neurodegenerative diseases. Generated from the website

The highest-quality personalized medications made specially for you